Official Title
Estudio Destinado a Valorar la Utilidad de Vitamina D Sobre Morbilidad y Mortalidad de la infección Por Virus SARS-COV-2 (COVID-19) en el Hospital Universitario Central de Asturias
Brief Summary

Patients diagnosed of COVID-19 disease are randomized to receive a single dose of 100.000 IU of Cholecalciferol (Vitamin D arm) or no vitamin D (on top of the current medication used to treat COVID 19). Clinical, radiological and biochemical outcomes of COVID 19 disease as well as mortality are evaluated.

Detailed Description

Efficacy parameters to compare both groups (vitamin D and No vitamin D).

Time to reach undetectable levels of SARS COV2 Infection.

Time of normalization of symptoms and clinical parameters.

Time of normalization of radiological images.

Time of normalization of biochemical markers.

Time of normalization of molecular inflammatory markers.

Transfer to the Intensive care Unit.

Mortality rate.

Unknown status
COVID-19

Drug: Cholecalciferol

Single doe of 100.000 IU
Other Name: Vitamin D

Eligibility Criteria

Inclusion Criteria:

- > 18 year

- Diagnosis of COVID-19

- Accept to participate in the study ( consent)

Exclusion Criteria:

- Pregnancy

- Allergy to vitamin D

- Consumption of any form of vitamin D during the last 3 months

- Expected fatal outcome in the next 24 hours

- Cognitive deterioration

Eligibility Gender
All
Eligibility Age
Minimum: N/A ~ Maximum: N/A
Countries
Spain
Locations

Hospital Universitario Central de Asturias
Oviedo, Asturias, Spain

Investigator: Jorge B Cannata-Andía, MD PhD
Contact: *34 985106137
cannata@hca.es

Contacts

Jorge B Cannata-Andía, MD PhD
*34 985 106137
cannata@hca.es

Juan Pérez-Ortega
*34 985109905
juan.perez@finba.es

Fundación para la Investigación Biosanitaria del Principado de Asturias
NCT Number
MeSH Terms
COVID-19
Vitamin D
Cholecalciferol